Several ICIs have been tested for their efficacy in GBM treatment, among which are those targeting PD-1 (Programmed Death-1) and PD-L1 (Programmed Death Ligand-1), as well as CTLA-4 (Cytotoxic T-Lymphocyte Antigen-4). Here, RPL17 is linked to glioblastoma.